Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma
- 6 June 2014
- journal article
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 41 (11), 2017-2022
- https://doi.org/10.1007/s00259-014-2822-7
Abstract
We investigated the prognostic value of total metabolic tumour volume (TMTV) in diffuse large B-cell lymphoma (DLBCL). TMTV was measured in 114 patients with newly diagnosed DLBCL who underwent 18F-FDG PET/CT at baseline before immunochemotherapy. TMTV was computed by summing the volumes of all lymphomatous lesions after applying the local SUVmax threshold of 41 % using semiautomatic software. Prognostic value was assessed by Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS). Median follow-up was 39 months. Average pretherapy TMTV was 509 ± 568 cm3. The 3-year estimates of PFS were 77 % in the low metabolic burden group (TMTV ≤550 cm3) and 60 % in the high metabolic burden group (TMTV >550 cm3, p = 0.04), and prediction of OS was even better (87 % vs. 60 %, p = 0.0003). Cox regression showed independence of TMTV for OS prediction (p = 0.002) compared with other pretherapy indices of tumour burden, such as tumour bulk and the International Prognostic Index. Pretherapy TMTV is an independent predictor of outcome in patients with DLBCL.Keywords
This publication has 18 references indexed in Scilit:
- Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in advanced-stage squamous cell carcinoma of the larynx and hypopharynxAnnals Of Oncology, 2013
- Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapyHematological Oncology, 2012
- Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvementAnnals of Hematology, 2011
- Impact of Concordant and Discordant Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated With R-CHOPJournal of Clinical Oncology, 2011
- Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending storyAnnals Of Oncology, 2010
- Immuno–Fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA StudyJournal of Clinical Oncology, 2009
- Standards for PET Image Acquisition and Quantitative Data AnalysisJournal of Nuclear Medicine, 2009
- Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) studyThe Lancet Oncology, 2008
- FDG-PET/CT in re-staging of patients with lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003